Plotnikov M B, Chernysheva G A, Smol'yakova V I, Plotnikova T M, Sysolyatin S V, Kryukov Y A
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Tomsk, Russia.
Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia.
Bull Exp Biol Med. 2018 Sep;165(5):625-628. doi: 10.1007/s10517-018-4228-1. Epub 2018 Sep 17.
We studied anti-ischemic activity of n-tyrozol under conditions of repeated transient myocardial ischemia in rats caused by repeated (5×3 min) occlusion of the left coronary artery. n-Tyrozol administered intraperitoneally in a dose of 20 mg/kg daily over 4 days before the ischemia modeling (the last injection 15 min prior to the start of the experiment) produced a clear-cut anti-ischemic effect: it reduced ST elevation and promoted more complete recovery of ECG during reperfusion. During reperfusion periods, n-tyrozol significantly decreased the risk of ventricular fibrillation and shortened the duration of tachyarrhythmia episodes (ventricular tachycardia and fibrillation).
